Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
When multiple myeloma (MM) patients decide to enroll in a clinical trial they are doing so in an effort to find some new therapy or combination of therapies that will reduce or even cure their incurable blood cancer. In essence, they are saying “you can experiment on me and I hope to find a therapy that works.”
In return for experimenting on myeloma patients, the organization doing the clinical trial (usually a for-profit company) has the requirement to publish the results of the clinical trial- good, bad or ugly.
MM patients enrolling in clinical trials deserve to know everything about the risks they are taking.
According to the second article below, the drug company doing the clinical trial is publishing the results only 8% of the time. Once the trial is completed the drug company thoroughly analyzes the results, right? So why aren’t these companies publishing the results?
The author of the article posted below thinks that the reason may be “disclosures that trial data containing safety or effectiveness information.”
I am a MM survivor and MM cancer coach. Don’t rely exclusively on conventional oncology for your care. Learn about and include evidence-based non-conventional, non-toxic MM therapies. I do.
Have you been diagnosed with MM? What therapies are you considering? Scroll down the page, post a question or comment and I will reply ASAP.
“Most people who enter a clinical trial for a cancer immunotherapy have advanced disease. They hope that the treatment, which aims to activate their T cells against cancer, will boost their life expectancy from months to years. In rare cases, however, the pendulum swings the other way and the treatment results in a fatal reaction.
Deaths in recent trials for three cancer immunotherapy drugs have put participants, researchers and drug companies on edge, largely because the causes of the deaths are not well understood…”
Only about 15,000 of the approximately 178,000 registered trials in the U.S.’s main database, ClinicalTrials.gov, currently include summaries of results, according to officials at the National Institutes of Health. That works out to a paltry 8%.
It is a cause for concern since the lack of results means that potentially important information about medicines is unknown…
The issue has been especially contentious for the pharmaceutical industry, which has endured scandals following disclosures that trial data containing safety or effectiveness information wasn’t previously disclosed.”